StreetAlpha
13F holdings · Q3 2026

NEA Management Company

Timonium, MD · files as NEA Management Company, LLC
Know the moment NEA Management Company filesYou follow NEA Management Company An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1512848

NEA Management Company reported 25 stocks worth $1.4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MBX (15.5%), SGP (14.1%) and TRVI (13.9%). Compared with Q2 2026, the fund trimmed GLUE and GOSS and sold out of KPTI.

Latest filing: what NEA Management Company did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new0 added2 trimmed1 sold outBought about $0 · sold about $29.3M
New 0

None

Added 0

None

Trimmed 2
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.4B−14.1% vs last quarter
Stocks held250 new · 1 sold out
Top 5 weight62.7%very concentrated
Turnover2%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
MBX
Mbx Biosciences Inc
$212M15.5%3.6MNo change8 of 8
2
SGP
Spyglass Pharma Inc
$192M14.1%7.4MNo change3 of 8
3
TRVI
Trevi Therapeutics Inc
$189M13.9%13.2MNo change8 of 8
4
CELC
Celcuity Inc
$136M10.0%1.7MNo change8 of 8
5
SVRA
Savara Inc
$126M9.3%24.5MNo change8 of 8
6
ZBIO
Zenas Biopharma Inc
$109M8.0%4MNo change8 of 8
7
GLUE
Monte Rosa Therapeutics Inc
$79.8M5.8%6.7M−1M (−13%)8 of 8
8
AUPH
Aurinia Pharmaceuticals Inc
$64.3M4.7%4MNo change8 of 8
9
COUR
Coursera Inc
$63.8M4.7%12.9MNo change8 of 8
10
CRSP
Crispr Therapeutics
$58.6M4.3%1.1MNo change8 of 8
🔒 15 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
KPTI
Karyopharm Therapeutics Inc
$5.6M577K

Reported value

last 8 quarters
$1.8BQ4 '24
$1.3BQ1 '25
$1.3BQ2 '25
$1.8BQ3 '25
$2BQ4 '25
$1.8BQ1 '26
$1.6BQ2 '26
$1.4BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

NEA Management Company 13F FAQ

What does NEA Management Company own?

NEA Management Company reported 25 stocks worth $1.4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are MBX (15.5%), SGP (14.1%) and TRVI (13.9%). The table above lists every position in the filing (the top 10 without an account).

What did NEA Management Company buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 0 added to, 2 trimmed and 1 sold out. It sold all of KPTI.

When will NEA Management Company file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is NEA Management Company's portfolio worth?

The Q3 2026 filing reports $1.4B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.